XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹

Clinical Outcomes

Request a Rep

XIENCE™ Stent Clinical Outcomes

Stent choice matters. And a wealth of clinical evidence supports the safety of the XIENCE™ Stent, which is why experts consider XIENCE™ Stent to be the gold standard among DES.¹

In addition, reproducible procedural outcomes are a proven quality of XIENCE™ DES performance,² delivering consistent patient safety with low complication rates.³

When choosing XIENCE™ Stent, interventional cardiologists (ICs) can know that the optimal outcomes they achieved in the cath lab will persist far into the future—not only treating stenosed vessels but enabling patients to have a better quality of life.⁴

There’s a Whole World of Evidence to Support the XIENCE™ Stent

XIENCE™ Stent is the world's leading DES, with over 20 million implants.⁵

Cardiologists have chosen XIENCE™ Stent for more than 15 million implants, making XIENCE™ Stent the world's leading DES

Cardiologists have chosen XIENCE™ Stent for over 120 clinical trials

Cardiologists have chosen XIENCE™ Stent for over 125,000 patients

Cardiologists have chosen XIENCE™ Stent for over 10 years

Substantial clinical data continue to provide evidence that XIENCE™ DES can effectively treat a broad spectrum of patients.¹ Given the best in class deliverability and the expanded treatment options of XIENCE Skypoint™ Stent,⁷ it is an excellent choice for complex patients.

Key XIENCE™ Stent Clinical Trials

XIENCE 28 & XIENCE 90 Data

XIENCE™ Stent—with either 1-month or 3-month dual antiplatelet therapy (DAPT)—reduced severe bleeding with no increase in ischaemic events.⁸

Short DAPT: Reduced Severe Bleeding⁸

With DAPT halted at either 1 month and 3 months, XIENCE™ Stent showed less severe bleeding, at 6 months and 12 months, vs earlier XIENCE™ Stent data

XIENCE 28: BARC 3-5 BLEEDING

Between 1 and 6 months

XIENCE 90: BARC 3-5 BLEEDING

Between 3 and 12 months

Note: PS stratified analysis for BARC 3-5 bleeding was not pre-specified.
Note: BARC 2-5 was a powered secondary endpoint.

Short DAPT: No Increase in Ischaemic Events in High Bleeding Risk (HBR) Patients⁸

With short DAPT data from both 1 month and 3 months, XIENCE™ Stent showed less severe bleeding than earlier XIENCE™ Stent findings

XIENCE 28: 1-month DAPT in HBR Patients
XIENCE 28: All Deaths or MI

Between 1 and 6 months

XIENCE 90: 3-month DAPT in HBR Patients
XIENCE 90: All Deaths or MI

Between 3 and 12 months

CARDIOBASE Registry: XIENCE™ Stent vs Synergy^‡

XIENCE™ Stent outperforms Synergy^‡ with short-term safety outcomes in real-world patients.⁹

Short-Term Data with XIENCE™ Stent and Synergy^‡

XIENCE™ Stent: Significantly Lower Acute Definite Stent Thrombosis vs Synergy^ǂ9

75% less acute definite stent thrombosis with XIENCE™ Stent System compared to Synergy^ǂ

XIENCE™ Stent results in 75% less acute definite stent thrombosis vs Synergyǂ

Propensity-matched analysis from a single-centre registry.

XIENCE™ Stent: Significantly Lower Target Lesion Revascularisation (TLR) at 1 Month vs Synergy^ǂ9

Suggests favourable economic benefits* for XIENCE Stent vs. Synergy^ǂin clinical practice

*Driven by reduction in additional procedures and hospitalisations

Compared to Synergyǂ, XIENCE™ Stent results in significantly lower TLR, and therefore economic benefits for clinical practice

Target Lesion Revascularisation

IDEAL-LM Data: Long-Term Complex Patient Data on XIENCE™ Stent vs Synergy^‡

In the left main subset of patients, the IDEAL-LM findings also reveal that the XIENCE™ Stent outperforms Synergy^‡ at 2 years¹⁰

Left Main Patients: XIENCE™ Stent Shows Significantly Lower Long-Term Definite Stent Thrombosis vs Synergy^ǂ10

XIENCE Stent
0% Stent Thrombosis

Definite Stent Thrombosis

RESOLUTE All-Comers (RAC) Randomised Trial: XIENCE™ Stent vs Resolute^‡

Safety data from RAC real-world patients also reveal that XIENCE™ Stent outperforms Resolute.^‡11

XIENCE™ Stent: Significantly Lower Early Definite Stent Thrombosis vs Resolute^ǂ11

88% less definite stent thrombosis with XIENCE™ Stent compared to Resolute^ǂ

Definite Stent Thrombosis

XIENCE™ Stent: Significantly Lower Late Definite Stent Thrombosis vs Resolute^ǂ11

75% less definite stent thrombosis with XIENCE™ Stent compared to Resolute^ǂ

Note: Primary endpoint for non-inferiority was met by Resolute^ǂ compared with XIENCE™ Stent. The primary endpoint of target lesion failure (TLF) was a composite of cardiac death, myocardial infarction, and clinically indicated target lesion revascularisation at 12 months.

Definite Stent Thrombosis

References:

Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
Saito S, et al. Eur Heart J. 2014;35:2021-2031. Saito S, et al. EuroIntervention. 2019;15(11):e1006-e1013. Natsuaki M, et al. J Am Coll Cardiol. 2013;62:181-190. Stone G, et al. Lancet 2018;392:1530-1540.
Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333.
Baron SJ, et al. J Am Coll Cardiol. 2017;70:3113-3122.
Data on file at Abbott. 20 million implants is based on DES data through Q4 2022.
Kufner S, et al. Circulation. 2019:139(3):325-333.
Data on file at Abbott. XIENCE Sierra™ 3.0 x 18 mm, n=5; Synergy^‡ 3.0 x 20 mm, n=5; Resolute^‡ Onyx 3.0 x 18 mm, n=5. XIENCE Skypoint™ Stent Instructions for Use (IFU). Refer to IFU for additional information.
Mehran R, et al. TCT Connect 2020, XIENCE 28/90.
Zanchin C. et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675.
Van Geuns RJ, et al. TCT 2019, IDEAL-LM.
Serruys P, et al. N Engl J Med. 2010;363:136-146.

Explore Abbott's technologies for your needs.

Access personalised education and training

How can we help? Reach Abbott’s fast support here.

MAT-2413718 V1.0

XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹

XIENCE™ Stent Clinical Outcomes

There’s a Whole World of Evidence to Support the XIENCE™ Stent

XIENCE™ Stent is the world's leading DES, with over 20 million implants.⁵